PTM Biosciences

Company Overview

Snapshot

Founded in November 2012 by Elinor Dahan and Yifat Merbl, PTM Biosciences operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing proteomics-based products for personalized medicine.

Business overview

PTM Biosciences is dedicated to advancing personalized medicine through the development of proteomics-based products and tools. The company's core technology, Post Translational Modifications Profiling, was conceived at Harvard Medical School and aims to reveal the physiological state of diseases by analyzing protein modifications. This proprietary platform provides key information for identifying novel drug targets, elucidating drug mechanisms of action, and discovering predictive biomarkers. PTM Biosciences serves the healthcare and life sciences industries, with applications in disease diagnosis, management, and drug development, particularly in areas like oncology and autoimmune diseases.

Company Intelligence Q&A

What is PTM Biosciences' primary focus?

PTM Biosciences is focused on advancing personalized medicine by developing proteomics-based products and tools for disease diagnosis, disease management, and drug development.

When was PTM Biosciences founded?

PTM Biosciences was founded in November 2012.

Who are the co-founders of PTM Biosciences?

The co-founders of PTM Biosciences are Elinor Dahan and Yifat Merbl.

What is the core technology developed by PTM Biosciences?

PTM Biosciences is developing and commercializing Post Translational Modifications Profiling, a technology conceived at Harvard Medical School, which uncovers the potential of protein modifications to reveal the physiological state of a disease.

What markets does PTM Biosciences target?

PTM Biosciences targets the healthcare and life sciences markets, with a focus on applications in areas such as oncology and autoimmune diseases like melanoma and SLE.